Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mesoblast Ltd ADR (MESO)

Mesoblast Ltd ADR (MESO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,967,287
  • Shares Outstanding, K 114,178
  • Annual Sales, $ 5,900 K
  • Annual Income, $ -87,960 K
  • EBIT $ -62 M
  • EBITDA $ -57 M
  • 60-Month Beta 3.54
  • Price/Sales 283.03
  • Price/Cash Flow N/A
  • Price/Book 3.48

Options Overview Details

View History
  • Implied Volatility 107.71% ( +10.20%)
  • Historical Volatility 136.29%
  • IV Percentile 58%
  • IV Rank 38.70%
  • IV High 270.05% on 02/26/24
  • IV Low 5.24% on 10/15/24
  • Put/Call Vol Ratio 0.36
  • Today's Volume 7,794
  • Volume Avg (30-Day) 2,974
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 44,989
  • Open Int (30-Day) 39,436

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.30 +62.04%
on 12/12/24
19.15 -12.84%
on 12/19/24
+6.58 (+65.08%)
since 11/22/24
3-Month
6.86 +143.29%
on 09/25/24
19.15 -12.84%
on 12/19/24
+9.42 (+129.57%)
since 09/24/24
52-Week
1.61 +936.65%
on 01/18/24
19.15 -12.84%
on 12/19/24
+14.53 (+672.69%)
since 12/22/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...

MESO : 16.69 (-3.13%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...

MESO : 16.69 (-3.13%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...

MESO : 16.69 (-3.13%)
Why Shares of Mesoblast Are Down Monday

The company's shares continued to tumble after it received a Complete Response Letter last week from the FDA.

MSB.AX : 2.550 (+0.79%)
MESO : 16.69 (-3.13%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...

MESO : 16.69 (-3.13%)
Why Shares of Mesoblast Are Plunging Friday

The company received a Complete Response Letter from the FDA regarding its prospective graft-versus-host disease therapy.

MSB.AX : 2.550 (+0.79%)
MESO : 16.69 (-3.13%)
Appendix 4C Quarterly Activity Report

Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022...

MSB.AX : 2.550 (+0.79%)
MESO : 16.69 (-3.13%)
Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management

NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...

MSB.AX : 2.550 (+0.79%)
MESO : 16.69 (-3.13%)
Mesoblast Key Opinion Leader Event Series for Investors & Analysts

Chronic Low Back Pain due to Degenerative Disc Disease...

MSB.AX : 2.550 (+0.79%)
MESO : 16.69 (-3.13%)
Operational Highlights and Financial Results for the Period Ended March 31, 2022

Substantial Reduction in Operational Spend while Maintaining Focus on BLA Resubmission...

MSB.AX : 2.550 (+0.79%)
MESO : 16.69 (-3.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's...

See More

Key Turning Points

3rd Resistance Point 20.10
2nd Resistance Point 18.80
1st Resistance Point 18.01
Last Price 16.69
1st Support Level 15.92
2nd Support Level 14.62
3rd Support Level 13.83

See More

52-Week High 19.15
Last Price 16.69
Fibonacci 61.8% 12.45
Fibonacci 50% 10.38
Fibonacci 38.2% 8.31
52-Week Low 1.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar